Handel Virios Therapeutics, Inc. - VIRI CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | 0.05 | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024068% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.001846% | ||||||||
| Gebyr natten over, tid | 21:00 (UTC) | ||||||||
| Min. handlet mængde | 1 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Nøglestatistikker
| Tidligere luk* | N/A |
| Åben* | N/A |
| 1-Års Ændring* | N/A |
| Dagens Spænd* | N/A |
| 52-Ugers Spænd | 0.22-9.11 |
| Gennemsnitlig Volumen (10 dage) | 453.52K |
| Gennemsnitlig Volumen (3 måneder) | 7.95M |
| Market Cap | 5.52M |
| P/E-forhold | -100.00K |
| Udestående aktier | 18.33M |
| Omsætning | N/A |
| EPS | -1.60 |
| Dividend (Udbytte %) | N/A |
| Beta | -100.00K |
| Næste indtjeningsopgørelse | N/A |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|---|---|---|---|---|---|
| Mar 6, 2023 | 0.39 | -0.02 | -4.88% | 0.41 | 0.43 | 0.39 |
| Oct 4, 2022 | 0.38 | 0.00 | 0.00% | 0.38 | 0.39 | 0.37 |
| Sep 28, 2022 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.37 |
| Sep 26, 2022 | 0.38 | -0.02 | -5.00% | 0.40 | 0.42 | 0.38 |
| Sep 23, 2022 | 0.40 | -0.03 | -6.98% | 0.43 | 0.43 | 0.39 |
| Sep 22, 2022 | 0.43 | -0.01 | -2.27% | 0.44 | 0.44 | 0.42 |
| Sep 21, 2022 | 0.45 | -0.03 | -6.25% | 0.48 | 0.48 | 0.42 |
| Sep 20, 2022 | 0.47 | -0.03 | -6.00% | 0.50 | 0.52 | 0.45 |
| Sep 19, 2022 | 1.96 | -0.88 | -30.99% | 2.84 | 2.84 | 1.88 |
| Sep 16, 2022 | 8.56 | 0.68 | 8.63% | 7.88 | 8.73 | 7.55 |
| Sep 15, 2022 | 7.44 | -0.23 | -3.00% | 7.67 | 7.77 | 7.21 |
| Sep 14, 2022 | 7.71 | -0.20 | -2.53% | 7.91 | 7.98 | 7.54 |
| Sep 13, 2022 | 7.81 | 0.33 | 4.41% | 7.48 | 8.02 | 7.32 |
| Sep 12, 2022 | 7.67 | 0.49 | 6.82% | 7.18 | 7.68 | 7.12 |
| Sep 9, 2022 | 7.03 | 0.05 | 0.72% | 6.98 | 7.12 | 6.97 |
| Sep 8, 2022 | 6.99 | 0.16 | 2.34% | 6.83 | 7.04 | 6.81 |
| Sep 7, 2022 | 6.81 | 0.01 | 0.15% | 6.80 | 6.98 | 6.76 |
| Sep 6, 2022 | 6.64 | -0.27 | -3.91% | 6.91 | 6.99 | 6.64 |
| Sep 2, 2022 | 6.90 | 0.07 | 1.02% | 6.83 | 6.99 | 6.70 |
| Sep 1, 2022 | 6.84 | 0.03 | 0.44% | 6.81 | 6.91 | 6.57 |
Virios Therapeutics, Inc. Events
| Tid (UTC) (UTC) | Land | Begivenhed |
|---|---|---|
| No events scheduled | ||
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 |
| Omsætning | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 15.6409 | 10.0054 | 2.1785 | 1.9615 |
| Salgs/Generelle/Admin. Udgifter, Total | 4.84525 | 9.81138 | 1.34232 | 1.10739 |
| Forskning & Udvikling | 10.7957 | 0.19401 | 0.83618 | 0.85411 |
| Driftsindtægter | -15.6409 | -10.0054 | -2.1785 | -1.9615 |
| Renteindkomst (Udgift), Netto Ikke-Drift | -0.31933 | -0.38422 | -0.29513 | -0.1521 |
| Andre, Netto | 0.04322 | 0 | 0.00001 | |
| Netto Indkomst Før Skat | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Netto Indkomst Efter Skat | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Netto Indkomst Før Ekstra Ting | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Netto Indkomst | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Fortyndet Netto Indkomst | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Fortyndet Vægtet Gennemsnit Aktier | 8.32931 | 8.30508 | 7.83249 | 7.83249 |
| Fortyndet EPS Uden Ekstraordinære Ting | -1.91616 | -1.24579 | -0.31582 | -0.26985 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
| Fortyndet Normaliseret EPS | -1.91616 | -1.24579 | -0.31582 | -0.26985 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Omsætning | 0 | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 3.96121 | 4.18756 | 4.11149 | 4.28446 | 3.05743 |
| Salgs/Generelle/Admin. Udgifter, Total | 1.19211 | 1.26915 | 1.15037 | 1.07526 | 1.35048 |
| Forskning & Udvikling | 2.7691 | 2.91841 | 2.96112 | 3.2092 | 1.70696 |
| Driftsindtægter | -3.96121 | -4.18756 | -4.11149 | -4.28446 | -3.05743 |
| Renteindkomst (Udgift), Netto Ikke-Drift | 0.00091 | -0.32374 | 0.00151 | 0.0015 | 0.0014 |
| Netto Indkomst Før Skat | -3.96031 | -4.51129 | -4.10998 | -4.28296 | -3.05603 |
| Netto Indkomst Efter Skat | -3.96031 | -4.51129 | -4.10998 | -4.28296 | -3.05603 |
| Netto Indkomst Før Ekstra Ting | -3.96031 | -4.51129 | -4.10998 | -4.28296 | -3.05603 |
| Netto Indkomst | -3.96031 | -4.51129 | -4.10998 | -4.28296 | -3.05603 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -3.96031 | -4.51129 | -4.10998 | -4.28296 | -3.05603 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -3.96031 | -4.51129 | -4.10998 | -4.28296 | -3.05603 |
| Fortyndet Netto Indkomst | -3.96031 | -4.51129 | -4.10998 | -4.28296 | -3.05603 |
| Fortyndet Vægtet Gennemsnit Aktier | 8.33039 | 8.3304 | 8.33039 | 8.33039 | 8.32601 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.4754 | -0.54155 | -0.49337 | -0.51414 | -0.36705 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Fortyndet Normaliseret EPS | -0.4754 | -0.54155 | -0.49337 | -0.51414 | -0.36705 |
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Totale Nuværende Aktiver | 15.7767 | 31.4727 | 0.3159 | 0.0424 |
| Likvider og Kortsigtede Investeringer | 14.0082 | 29.7954 | 0.30938 | 0.03003 |
| Cash | 14.0082 | 29.7954 | 0.30938 | 0.03003 |
| Prepaid Expenses | 1.7685 | 1.67737 | 0.00652 | 0.01237 |
| Total Assets | 15.7767 | 31.4727 | 0.3159 | 0.06594 |
| Other Long Term Assets, Total | 0 | 0.02354 | ||
| Total Current Liabilities | 1.27562 | 1.53184 | 1.62087 | 1.32633 |
| Accounts Payable | 0.35386 | 0.36891 | 0.03542 | 0.14566 |
| Accrued Expenses | 0.92176 | 1.16294 | 1.58545 | 1.18068 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.27562 | 1.53184 | 5.25841 | 1.32633 |
| Total Long Term Debt | 0 | 0 | 3.63754 | 0 |
| Long Term Debt | 0 | 3.63754 | 0 | |
| Total Equity | 14.5011 | 29.9409 | -4.94251 | -1.2604 |
| Preferred Stock - Non Redeemable, Net | 0 | 0.075 | 1.28348 | |
| Common Stock | 0.00083 | 0.00083 | 12.6012 | 12.6012 |
| Retained Earnings (Accumulated Deficit) | -43.9254 | -27.9651 | -17.6187 | -15.1451 |
| Total Liabilities & Shareholders’ Equity | 15.7767 | 31.4727 | 0.3159 | 0.06594 |
| Total Common Shares Outstanding | 8.33039 | 8.30508 | 7.83249 | 7.83249 |
| Additional Paid-In Capital | 58.4256 | 57.9052 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 12.5499 | 15.7767 | 20.1072 | 23.7648 | 28.2745 |
| Likvider og Kortsigtede Investeringer | 11.3522 | 14.0082 | 19.1863 | 21.8351 | 24.5856 |
| Cash | 11.3522 | 14.0082 | 19.1863 | 21.8351 | 24.5856 |
| Prepaid Expenses | 1.19769 | 1.7685 | 0.92091 | 1.92969 | 3.68898 |
| Total Assets | 12.5499 | 15.7767 | 20.1072 | 23.7648 | 28.2745 |
| Total Current Liabilities | 1.8772 | 1.27562 | 1.22679 | 0.90626 | 1.16729 |
| Accounts Payable | 0.33069 | 0.35386 | 0.4835 | 0.26259 | 0.61466 |
| Accrued Expenses | 1.54651 | 0.92176 | 0.74329 | 0.64367 | 0.55264 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.8772 | 1.27562 | 1.22679 | 0.90626 | 1.16729 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 10.6727 | 14.5011 | 18.8804 | 22.8585 | 27.1072 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | |||
| Common Stock | 0.00083 | 0.00083 | 0.00083 | 0.00083 | 0.00083 |
| Additional Paid-In Capital | 58.5575 | 58.4256 | 58.2937 | 58.1618 | 58.1275 |
| Retained Earnings (Accumulated Deficit) | -47.8857 | -43.9254 | -39.4141 | -35.3041 | -31.0211 |
| Total Liabilities & Shareholders’ Equity | 12.5499 | 15.7767 | 20.1072 | 23.7648 | 28.2745 |
| Total Common Shares Outstanding | 8.33039 | 8.33039 | 8.33039 | 8.33039 | 8.33039 |
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Netto indkomst/Startlinje | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Likvider Fra Driftsaktiviteter | -15.6896 | -3.8952 | -2.09215 | -1.19596 |
| Ikke-Likvide Ting | 0.32288 | 7.42526 | 0.065 | 0.04851 |
| Ændringer i Driftskapital | -0.05219 | -0.97406 | 0.31648 | 0.86913 |
| Likvider fra Financieringsaktiviteter | -0.0976 | 33.3812 | 2.37151 | 1.15047 |
| Financiering af Cash-Flow-Ting | -0.29517 | -0.13826 | -0.05849 | 1.15047 |
| Udstedelse (Pensionering) af Gæld, Netto | 0 | 1.99413 | 2.43 | 0 |
| Netto Ændring i Likviditet | -15.7872 | 29.486 | 0.27936 | -0.04549 |
| Likvid Rente Betalt | 0 | 0.01255 | ||
| Udstedelse (Pensionering) af Aktier, Netto | 0.19756 | 31.5253 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -3.96031 | -15.9603 | -11.449 | -7.339 | -3.05603 |
| Cash From Operating Activities | -2.65602 | -15.6896 | -10.5114 | -7.86267 | -5.1122 |
| Non-Cash Items | 0.13191 | 0.32288 | 0.19098 | 0.05907 | 0.02483 |
| Changes in Working Capital | 1.17239 | -0.05219 | 0.74656 | -0.58274 | -2.08099 |
| Cash From Financing Activities | 0 | -0.0976 | -0.0976 | -0.0976 | -0.0976 |
| Financing Cash Flow Items | 0 | -0.29517 | -0.29517 | -0.29517 | -0.29517 |
| Issuance (Retirement) of Stock, Net | 0 | 0.19756 | 0.19756 | 0.19756 | 0.19756 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
| Net Change in Cash | -2.65602 | -15.7872 | -10.609 | -7.96027 | -5.20981 |
| Cash Interest Paid | 0 | 0 |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| Corday (Brian David) | Individual Investor | 6.2724 | 1149749 | 76797 | 2023-02-13 | LOW |
| Pridgen (William L) | Individual Investor | 4.0694 | 745944 | 13691 | 2022-12-31 | LOW |
| Ionic Ventures LLC | Venture Capital | 3.804 | 697292 | -1132708 | 2022-12-31 | MED |
| Renaissance Technologies LLC | Hedge Fund | 1.2842 | 235400 | 58800 | 2022-12-31 | HIGH |
| Walleye Capital LLC | Hedge Fund | 0.8964 | 164314 | 14314 | 2022-12-31 | HIGH |
| Warberg Asset Management LLC | Hedge Fund | 0.8729 | 160000 | -40000 | 2022-12-31 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.811 | 148651 | -93015 | 2022-12-31 | LOW |
| Burch (Richard Alan) | Individual Investor | 0.8057 | 147681 | 0 | 2022-12-31 | LOW |
| Envestnet Asset Management, Inc. | Investment Advisor | 0.5957 | 109196 | 93050 | 2022-12-31 | LOW |
| PVG Asset Management Corporation | Investment Advisor | 0.4397 | 80590 | 0 | 2022-12-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3289 | 60286 | 0 | 2022-12-31 | LOW |
| Koshinski Asset Management, Inc | Investment Advisor | 0.2233 | 40924 | 0 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2068 | 37911 | 896 | 2022-12-31 | LOW |
| Duncan (Gregory Scott) | Individual Investor | 0.1771 | 32461 | 0 | 2022-12-31 | LOW |
| Ergoteles Capital | Hedge Fund | 0.1763 | 32309 | 32309 | 2022-12-31 | HIGH |
| Raymond James & Associates, Inc. | Research Firm | 0.1637 | 30000 | -5000 | 2022-12-31 | LOW |
| Advisor Group, Inc | Investment Advisor | 0.1518 | 27829 | 19208 | 2022-12-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 0.1121 | 20541 | 9233 | 2022-12-31 | HIGH |
| Cetera Advisors LLC | Investment Advisor | 0.112 | 20524 | -23420 | 2022-12-31 | MED |
| Regions Investment Management, Inc. | Investment Advisor | 0.1095 | 20072 | 0 | 2022-12-31 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
Handelskurtage
0
- 1:1
Gearing
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
Virios Therapeutics, Inc. Company profile
Om Virios Therapeutics, Inc.
Virios Therapeutics, Inc. tidligere Virios Therapeutics, LLC. er en bioteknologisk virksomhed i udviklingsfasen, der fokuserer på at udvikle antivirale terapier til behandling af sygdomme, der er forbundet med et viralt udløst unormalt immunrespons, såsom fibromyalgi (FM). Virksomhedens førende udviklingskandidat er IMC-1, som er en fast dosiskombination af famciclovir og celecoxib. IMC-1 er en kombineret antiviral behandling, der er udviklet til synergistisk at undertrykke aktivering og replikation af Herpes Simplex Virus-1 (HSV-1). Dens HSV-1 er den grundlæggende årsag til kroniske sygdomme såsom FM, irritabel tarmsygdom (IBS), kronisk træthedssyndrom og funktionelt somatisk syndrom. Virksomheden er ved at udvikle sin første kandidat, IMC-1, til mennesker, der lider af fibromyalgi.
| Industry: | Bio Therapeutic Drugs |
44 Milton Avenue
ALPHARETTA
GEORGIA 30009
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com